...
首页> 外文期刊>Leukemia and lymphoma >Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement.
【24h】

Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement.

机译:18F-氟脱氧葡萄糖正电子发射断层扫描/计算断层摄影分期在新诊断的古典霍奇金淋巴瘤中的影响:患有阶段疾病的案例较少,骨骼受累。

获取原文
获取原文并翻译 | 示例
           

摘要

(18)F-Fluorodeoxyglucose positron emission tomography/ computed tomography (PET/CT) is a highly accurate staging method in classical Hodgkin lymphoma (cHL). We retrospectively compared the staging results obtained in two large cohorts of patients with cHL diagnosed before (n = 324) and after (n = 406) the introduction of PET/CT staging in a retrospective study. In PET/CT staged patients, stage I disease was less frequent (16% vs. 27%, p < 0.001) while stage IV disease was more frequent (17% vs. 10%, p = 0.02). Imaging-detected skeletal involvement was recognized more often in PET/CT staged patients (17% vs. 2%, p < 0.001), and the presence of focal skeletal PET/CT lesions was associated with higher risk of progression (hazard ratio [HR] 1.96, 95% confidence interval [CI]: 1.14-3.36). The German Hodgkin Study Group (GHSG) risk classification (early, intermediate, advanced disease) predicted outcome in PET/CT staged patients. In conclusion, PET/CT led to higher disease stages, and the more frequently diagnosed skeletal lesions may be an adverse prognostic factor.
机译:(18)F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(PET / CT)是典型霍奇金淋巴瘤(CHL)中的高精度分期方法。我们回顾性地比较了在诊断为(n = 324)的CHL患者的两种患者中获得的分期结果(n = 406)在回顾性研究中引入PET / CT分段。在PET / CT分阶段患者中,I阶段疾病的频率较低(16%对27%,P <0.001),而阶段IV疾病更频繁(17%vs.10%,P = 0.02)。 PET / CT分阶段患者(17%vs.2%,P <0.001)更常识地识别成像骨骼参与,并且存在局灶性骨骼PET / CT病变的存在与较高的进展风险(危害比率[HR ] 1.96,95%置信区间[CI]:1.14-3.36)。德国霍奇金研究组(GHSG)风险分类(早期,中级,晚期疾病)预测PET / CT分期患者的结果。总之,PET / CT导致疾病阶段更高,并且较常见的骨骼病变可能是不良预后因子。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号